RYVAX | VENAX | RYVAX / VENAX | |
Total Expense Ratio | 1.63 | 0.09 | 1,811% |
Annual Report Gross Expense Ratio | 1.68 | 0.09 | 1,867% |
Fund Existence | 28 years | 21 years | - |
Gain YTD | -10.722 | 0.243 | -4,410% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 100000 | 3% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 4.22M | 8.85B | 0% |
Annual Yield % from dividends | 0.00 | 3.06 | - |
Returns for 1 year | -12.78 | -4.10 | 312% |
Returns for 3 years | 4.38 | 5.56 | 79% |
Returns for 5 years | 118.35 | 198.45 | 60% |
Returns for 10 years | -59.19 | 29.08 | -204% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
LRMAX | 26.06 | 0.04 | +0.15% |
Lord Abbett Dividend Growth F3 | |||
FBONX | 39.01 | 0.04 | +0.10% |
American Funds American Balanced 529-F-3 | |||
CVMAX | 22.46 | 0.01 | +0.04% |
Calvert Emerging Markets Equity A | |||
RSEFX | 15.30 | -0.02 | -0.13% |
Royce Small-Cap Special Equity Svc | |||
ICPUX | 6.69 | -0.01 | -0.15% |
Integrity Mid-North American Resources C |